Bg pattern

YTTRIGA PRECURSOR RADIOFARMACEUTICO EN SOLUCION - Radiopharmaceutical precursor in solution

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use YTTRIGA PRECURSOR RADIOFARMACEUTICO EN SOLUCION - Radiopharmaceutical precursor in solution

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

PACKAGE LEAFLET: INFORMATION FOR THE USER

Yttriga radiopharmaceutical precursor in solution.

Chloride of (90Y) yttrium

Read all of this leaflet carefully before you start using this medicine.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

In this leaflet:

  1. What is Yttriga and what is it used for
  2. Before you use Yttriga
  3. How to use Yttriga
  4. Possible side effects
  5. Storage of Yttriga
  6. Further information

1. What is YTTRIGA and what is it used for

Yttriga is a radioactive medicinal product used in combination with another medicinal product that targets specific cells in the body.

When the target is reached, Yttriga provides tiny doses of radiation to these specific sites.

For more information about the treatment and possible effects caused by the radiolabelled medicinal product, see the package leaflet of the medicinal product used in combination.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. Before you use YTTRIGA

Do not use Yttriga:

  • if you are allergic (hypersensitive) to chloride of (90Y) yttrium or any of the other components of Yttriga.
  • if you are pregnant or if there is a possibility that you may be pregnant (see below).

Take special care with Yttriga:

Yttriga is a radioactive medicinal product and is only used in combination with another medicinal product.

Its intended use is not direct administration to patients.

Due to strict laws regarding the use, handling, and disposal of radiopharmaceuticals, this product must be used exclusively in a hospital or similar facility. It must be handled and administered exclusively by qualified and trained personnel for the safe treatment of radioactive materials.

Special care should be taken when administering radioactive medicinal products to children and adolescents (from 2 to 16 years of age).

Use of other medicinal products

Tell your doctor or pharmacist if you are using or have recently used any other medicinal products, including those obtained without a prescription.

The interaction of chloride of (90Y) yttrium with other medicinal products is unknown, as no clinical studies are available.

Pregnancy

Yttriga is contraindicated in pregnancy.

Tell your doctor if there is any possibility that you may be pregnant. If you experience a delay in your menstrual period, you should assume you are pregnant until proven otherwise.

Your doctor will consider the possibility of using alternative techniques that do not involve the use of ionizing radiation.

Women of childbearing age must use effective contraceptive methods during and after treatment.

Breast-feeding

Your doctor will ask you to interrupt breast-feeding.

Ask your doctor or pharmacist for advice before taking any medicinal product.

3. How to use YTTRIGA

Your doctor will not administer Yttriga directly.

Dose.

Your doctor will decide what quantity of Yttriga you will receive for treatment.

Method of administration

YTTRIGA is a radioactive medicinal product used in combination with another medicinal product that targets specific cells in the body and is administered by your doctor.

If Yttriga is administered inadvertently

Yttriga is administered by your doctor after combining it with another medicinal product under strictly controlled conditions. The risk of receiving a possible overdose is small. However, if this occurs, you will receive appropriate treatment from your doctor.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicinal products, Yttriga can cause side effects, although not everybody gets them.

For more information, see the package leaflet of the specific medicinal product that will be radiolabelled.

If you experience any side effect not mentioned in this leaflet or if you experience any of the side effects described as severe, tell your doctor or pharmacist.

Reporting of side effects

If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicinal product.

5. Storage of YTTRIGA

Keep out of the reach and sight of children.

Do not use Yttriga after the expiry date stated on the label after EXP.

Storage must be carried out in accordance with local regulations for radioactive substances.

Disposal of unused medicinal product and all materials that have come into contact with it will be carried out in accordance with local regulations.

6. FURTHER INFORMATION

What contains Yttriga?

  • The active substance is chloride of (90Y) yttrium.
  • 1 ml of sterile solution contains 0.1-300 GBq of (90Y) yttrium on the reference date and time (equivalent to 0.005-15 micrograms of (90Y) yttrium) (as chloride of (90Y) yttrium).
  • The other components are hydrochloric acid (0.04 M).

Appearance and packaging of Yttriga

Colourless glass type I vial of 3 ml with a V-shaped bottom or a colourless glass type I vial with a flat bottom of 10 ml with a silicone plug, sealed with an aluminium seal.

Radiopharmaceutical precursor in solution.

Transparent and colourless sterile solution

Marketing authorisation holder

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Str. 10

D-13125 Berlin

Germany

Tel +49- 30-941084-280

Fax +49- 30-941084-470

e-mail: [email protected]

Manufacturer

Eckert & Ziegler Radiopharma GmbH

Branch Braunschweig

Gieselweg 1

D-38110 Braunschweig

Germany

You can obtain further information on this medicinal product from the representative of the marketing authorisation holder in your country:

Belgium

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Straße 10

D-13125 Berlin

Tel: +49-30-941084-280

[email protected]

Lithuania

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Straße 10

D-13125 Berlin

Tel: +49-30-941084-280

[email protected]

Bulgaria

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Straße 10

D-13125 Berlin

Tel: +49-30-941084-280

[email protected]

Luxembourg

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Straße 10

D-13125 Berlin

Tel: +49-30-941084-280

[email protected]

Czech Republic

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Straße 10

D-13125 Berlin

Tel: +49-30-941084-280

[email protected]

Hungary

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Straße 10

D-13125 Berlin

Tel: +49-30-941084-280

[email protected]

Denmark

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Straße 10

D-13125 Berlin

Tel: +49-30-941084-280

[email protected]

Malta

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Straße 10

D-13125 Berlin

Tel: +49-30-941084-280

[email protected]

Germany

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Straße 10

D-13125 Berlin

Tel: +49-30-941084-280

[email protected]

Netherlands

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Straße 10

D-13125 Berlin

Tel: +49-30-941084-280

[email protected]

Estonia

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Straße 10

D-13125 Berlin

Tel: +49-30-941084-280

[email protected]

Norway

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Straße 10

D-13125 Berlin

Tel: +49-30-941084-280

[email protected]

Greece

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Straße 10

D-13125 Berlin

Tel: +49-30-941084-280

[email protected]

Austria

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Straße 10

D-13125 Berlin

Tel: +49-30-941084-280

[email protected]

Spain

NUCLIBER, S.A.

C/ Hierro, 33

E-28045 Madrid

Tel: +34 915 062 940

[email protected]

Poland

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Straße 10

D-13125 Berlin

Tel: +49-30-941084-280

[email protected]

France

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Straße 10

D-13125 Berlin

Tel: +49-30-941084-280

[email protected]

Portugal

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Straße 10

D-13125 Berlin

Tel: +49-30-941084-280

[email protected]

Croatia

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Straße 10

D-13125 Berlin

Tel: +49-30-941084-280

[email protected]

Romania

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Straße 10

D-13125 Berlin

Tel: +49-30-941084-280

[email protected]

Ireland

Advanced Accelerator Applications (UK & Ireland) Ltd.

Edison House, 223-231 Old Marylebone Road,

London, NW1 5QT – UK

Tel: +44 (0)2072585252

[email protected]

Slovenia

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Straße 10

D-13125 Berlin

Tel: +49-30-941084-280

[email protected]

Iceland

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Straße 10

D-13125 Berlin

Tel: +49-30-941084-280

[email protected]

Slovak Republic

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Straße 10

D-13125 Berlin

Tel: +49-30-941084-280

[email protected]

Italy

Campoverde srl

Via Quintiliano, 30

I-20138 Milano

Tel: +39-02-58039045

[email protected]

Finland

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Straße 10

D-13125 Berlin

Tel: +49-30-941084-280

[email protected]

Cyprus

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Straße 10

D-13125 Berlin

Tel: +49-30-941084-280

[email protected]

Sweden

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Straße 10

D-13125 Berlin

Tel: +49-30-941084-280

[email protected]

Latvia

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Straße 10

D-13125 Berlin

Tel: +49-30-941084-280

[email protected]

United Kingdom

Advanced Accelerator Applications (UK & Ireland) Ltd.

Edison House, 223-231 Old Marylebone Road,

London, NW1 5QT – UK

Tel: +44 (0)2072585252

[email protected]

Date of last revision of this leaflet:{MM/YYYY}.

Other sources of information

Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu.

The leaflet can be found in all languages of the European Union/European Economic Area on the European Medicines Agency website.

.

Online doctors for YTTRIGA PRECURSOR RADIOFARMACEUTICO EN SOLUCION - Radiopharmaceutical precursor in solution

Discuss questions about YTTRIGA PRECURSOR RADIOFARMACEUTICO EN SOLUCION - Radiopharmaceutical precursor in solution, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

0.0 (0)
Doctor

Andreea Mateescu

Paediatrics 8 years exp.

Dr Andreea Mateescu is a board-certified paediatrician with 7 years of clinical experience. She graduated from Carol Davila University of Medicine and Pharmacy in Bucharest, Romania, and completed her paediatric residency at INSMC Alessandrescu-Rusescu. She also holds additional training in general ultrasound diagnostics.

Dr Mateescu focuses on providing high-quality, evidence-based medical care for children, with a strong emphasis on prevention, healthy development, and long-term wellbeing. She believes that clear, empathetic communication with both children and parents is essential for building trust and ensuring effective care.

Online consultations with Dr Mateescu are suitable for:

  • preventive check-ups and monitoring of growth and development;
  • vaccination planning, including personalised and catch-up schedules;
  • assessment of psychomotor, emotional, and physical development;
  • diagnosis and management of acute and chronic paediatric conditions;
  • nutritional guidance for infants and children, including formula selection when medically indicated;
  • care for children with complex or rare conditions;
  • practical guidance and ongoing support for parents.
Dr Mateescu works with patience, empathy, and professionalism, ensuring that each child receives attentive, individualised care. Her goal is to support healthy, balanced development while helping parents feel confident and well-informed at every stage of their child’s care.
Camera Book a video appointment
€60

Frequently Asked Questions

Is a prescription required for YTTRIGA PRECURSOR RADIOFARMACEUTICO EN SOLUCION - Radiopharmaceutical precursor in solution?
YTTRIGA PRECURSOR RADIOFARMACEUTICO EN SOLUCION - Radiopharmaceutical precursor in solution requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
Who manufactures YTTRIGA PRECURSOR RADIOFARMACEUTICO EN SOLUCION - Radiopharmaceutical precursor in solution?
YTTRIGA PRECURSOR RADIOFARMACEUTICO EN SOLUCION - Radiopharmaceutical precursor in solution is manufactured by Eckert & Ziegler Radiopharma Gmbh. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of YTTRIGA PRECURSOR RADIOFARMACEUTICO EN SOLUCION - Radiopharmaceutical precursor in solution online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether YTTRIGA PRECURSOR RADIOFARMACEUTICO EN SOLUCION - Radiopharmaceutical precursor in solution is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to YTTRIGA PRECURSOR RADIOFARMACEUTICO EN SOLUCION - Radiopharmaceutical precursor in solution?
Other medicines with the same active substance () include LUTATHERA 370 MBq/mL SOLUTION FOR INFUSION, PLUVICTO 1000 MBq/mL Injectable Solution and Perfusion Solution, Xofigo 1100 kBq/ml injectable solution. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media